Zim Laboratories Ltd

Zim Laboratories Investor Presentation: Key Takeaways

Q2 FY27 operating income ₹1,054 Mn (+18.9% YoY), EBITDA ₹77 Mn at 7.3% margin, PAT loss ₹21 Mn. EU-GMP cost base weighs on margins.

Zim Laboratories Q2 FY27 Results: Net Loss of ₹2 Cr, Loss Widens

Zim Laboratories Ltd reported revenue from operations of ₹105.4 Cr (+18.8% YoY) and a net loss of ₹2 Cr for Q2 FY27.

Key figure

Net loss ₹2 Cr

Zim Laboratories Board Meeting Date

Zim Laboratories has scheduled a board meeting on 4 November 2026 to consider its unaudited quarterly results for the quarter ended 30 September 2026. The trading window stays closed from 1 October to 6 November 2026.

Zim Laboratories Regulatory Approval

Zim Laboratories received TGA GMP certification from Australia's Therapeutic Goods Administration for its Nagpur manufacturing facility. The certification covers various dosage forms and is valid until June 2028.

From

Therapeutic Goods Administration (TGA), Australia

Zim Laboratories Credit Rating

CARE Ratings has reaffirmed the credit ratings of Zim Laboratories Limited for its bank facilities, revising the outlook on long-term facilities to negative.

Zim Laboratories Other Announcement

Zim Laboratories Limited filed a certificate confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.

Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr

ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.

Value

₹14,04,640 Cr

Zim Laboratories Merger & Restructuring

ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.

Zim Laboratories Acquisition Worth ₹1.56 Cr

ZIM WOS completed a ₹1.56 Crore investment in stepdown ZIM Scientific Office L.L.C., Dubai, fulfilling the board-approved capital plan. The transaction closes the acquisition announced in August 2025.

Value

₹1.56 Cr

Zim Laboratories Merger & Restructuring Worth ₹2.38 Cr

Zim Laboratories confirmed that its subsidiary, ZIM FZE, completed the previously announced AED 9,16,000 investment in its step-down subsidiary, ZIM Scientific Office LLC.

Value

₹2.38 Cr

Zim Laboratories Other Announcement

A periodic shareholding pattern filing for Zim Laboratories Ltd for the quarter ended March 31, 2026, disclosing promoter and public shareholding details.

Zim Laboratories Investor Presentation: Key Takeaways

Zim Laboratories reported 31.2% YoY revenue growth in Q1 FY27, driven by core pharma and exports (84% of income). Strategy focuses on EU-GMP remediation and expanding the innovation-led NIP/OTF portfolio.

Call

Guides 32% growth

Zim Laboratories Annual General Meeting

Zim Laboratories Limited has announced the successful passing of Special Resolutions through a postal ballot, approving the remuneration structure for its Managing and Whole-Time Directors.

Zim Laboratories Investor Presentation: Key Takeaways

Q1 FY27 Total Operating Income rose 31.2% YoY to ₹942 Mn. However, EBITDA fell 40% to ₹34 Mn due to utility/employee costs.

Zim Laboratories Q1 FY27 Results: Net Loss of ₹4 Cr, Loss Widens

Zim Laboratories Ltd reported revenue from operations of ₹94.2 Cr (+31.2% YoY) and a net loss of ₹4 Cr for Q1 FY27.

Key figure

Net loss ₹4 Cr

Zim Laboratories Board Meeting Date

Zim Laboratories Limited has scheduled a board meeting for August 6, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.

Zim Laboratories Employee Stock Options

Zim Laboratories allotted 1,09,451 equity shares under its ESOP scheme. Total paid-up capital increased to 5,36,58,488 shares.

Zim Laboratories Employee Stock Options

Zim Laboratories allotted 1,09,451 equity shares under its ESOP/ESPS scheme. This increased the company's paid-up share capital to Rs 53.66 Crore.

Value

₹1.09 Cr

Zim Laboratories Employee Stock Options

ZIM Laboratories allotted 1,09,451 ESOP shares, realizing Rs.84.71 lakh (≈0.85 Crore). The allotment increases paid-up equity capital to Rs.53.66 Crore.

Value

₹0.85 Cr

Zim Laboratories Annual General Meeting

ZIM Laboratories issued a Postal Ballot notice to revise remuneration for its MD and Whole-Time Director. Total proposed annual compensation for both executives is Rs. 5.5 Crore.

Value

₹5.50 Cr

Zim Laboratories Annual General Meeting

ZIM Laboratories issued a Postal Ballot notice for shareholder approval of revised remuneration for its Managing Director and Whole-Time Director. Remote e-voting runs from July 13 to August 11.

Zim Laboratories Annual General Meeting

Zim Laboratories held its 42nd Annual General Meeting on June 29, 2026. The proceedings included adoption of financial statements and director appointments.

Zim Laboratories Promoter Buying (Off-Market)

Dr. Anwar Daud acquired 80,000 shares from Mr. Zulfiquar Kamal in an inter-se promoter transfer. This internal consolidation does not change overall promoter control.

Zim Laboratories Annual General Meeting

ZIM Laboratories scheduled its 42nd Annual General Meeting for June 29, 2026. Key agenda items include adopting financial statements and re-appointing Executive Director Mr. Zulfiquar Kamal.

Zim Laboratories Annual Report

ZIM Laboratories released its FY 2025-26 Annual Report and 42nd AGM notice. The meeting is scheduled for June 29, 2026, via video conferencing.

Zim Laboratories Promoter Buying (Off-Market): ₹0.69 Cr

ZIM Laboratories promoter Dr. Anwar Daud proposes to acquire 80,000 shares from another promoter via an inter-se transfer. The ₹0.69 Crore transaction maintains aggregate promoter control.

Value

₹0.69 Cr

Execution

on or after 11th June 2026

Zim Laboratories Earnings Call: Key Takeaways

Zim Laboratories reported FY26 revenue of ₹3,744M, flat YoY, impacted by geopolitical issues in the MENA region and EU GMP constraints. Strategy focuses on remediation and transitioning from R&D to execution.

Zim Laboratories Earnings Call: Key Takeaways

Zim Laboratories reported FY26 revenue of ₹3,744 Mn with 11.1% EBITDA margin. Strategy shifts towards innovative products (NIP/OTF) despite regulatory headwinds and geopolitical logistics challenges.

Zim Laboratories Regulatory Approval

Zim Laboratories received Italian regulatory approval for its Dabigatran Etexilate capsules. This authorization facilitates market entry into Italy and potential expansion across Europe.

Zim Laboratories Management Change

Zim Laboratories appointed M/s Dhananjay V. Joshi & Associates as Cost Auditor for FY 2026-27. This ensures regulatory compliance and oversight for the upcoming fiscal year.

Execution

F.Y. 2026-27